Literature DB >> 28074351

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.

Jonas Cicenas1,2,3, Linas Tamosaitis4, Kotryna Kvederaviciute5, Ricardas Tarvydas6, Gintare Staniute6, Karthik Kalyan6,7, Edita Meskinyte-Kausiliene8, Vaidotas Stankevicius9, Mindaugas Valius10.   

Abstract

Cancers are the group of diseases, which arise because of the uncontrolled behavior of some of the genes in our cells. There are possibilities of gene amplifications, overexpressions, deletions and other anomalies which might lead to the development and spread of cancer. One of the most dangerous ways to the cancers is the mutations of the genes. The mutated genes can start unstoppable proliferation of cells, their uncontrolled motility, protection from apoptosis, the DNA mutation enhancement as well as other anomalies, leading to the cancer. This review focuses on the genes, which are frequently mutated in various cancers and are known to be important in the advance and progression of colorectal cancer and melanoma, namely KRAS, NRAS and BRAF.

Entities:  

Keywords:  BRAF; Colorectal cancer; GTPase; KRAS; Kinase; Melanoma; Mutation; NRAS; Squamous cell anal cancer

Mesh:

Substances:

Year:  2017        PMID: 28074351     DOI: 10.1007/s12032-016-0879-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  106 in total

1.  Arf, Arl, Arp and Sar proteins: a family of GTP-binding proteins with a structural device for 'front-back' communication.

Authors:  Sebastiano Pasqualato; Louis Renault; Jacqueline Cherfils
Journal:  EMBO Rep       Date:  2002-11       Impact factor: 8.807

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

Review 4.  Localization and function of Arf family GTPases.

Authors:  J G Donaldson; A Honda
Journal:  Biochem Soc Trans       Date:  2005-08       Impact factor: 5.407

Review 5.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

6.  Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Authors:  Jean Jacques Grob; Mayur M Amonkar; Boguslawa Karaszewska; Jacob Schachter; Reinhard Dummer; Andrzej Mackiewicz; Daniil Stroyakovskiy; Kamil Drucis; Florent Grange; Vanna Chiarion-Sileni; Piotr Rutkowski; Mikhail Lichinitser; Evgeny Levchenko; Pascal Wolter; Axel Hauschild; Georgina V Long; Paul Nathan; Antoni Ribas; Keith Flaherty; Peng Sun; Jeffrey J Legos; Diane Opatt McDowell; Bijoyesh Mookerjee; Dirk Schadendorf; Caroline Robert
Journal:  Lancet Oncol       Date:  2015-10       Impact factor: 41.316

Review 7.  Role of Rho GTPases in breast cancer.

Authors:  Yong Tang; Lola Olufemi; Man-Tzu Wang; Daotai Nie
Journal:  Front Biosci       Date:  2008-01-01

Review 8.  The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.

Authors:  Gholamreza Safaee Ardekani; Seyed Mehdi Jafarnejad; Larry Tan; Ardavan Saeedi; Gang Li
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 9.  The Ras protein superfamily: evolutionary tree and role of conserved amino acids.

Authors:  Ana Maria Rojas; Gloria Fuentes; Antonio Rausell; Alfonso Valencia
Journal:  J Cell Biol       Date:  2012-01-23       Impact factor: 10.539

10.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

View more
  40 in total

1.  RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Authors:  Oghenekevwe M Gbenedio; Caroline Bonnans; Delphine Grun; Chih-Yang Wang; Ace J Hatch; Michelle R Mahoney; David Barras; Mary Matli; Yi Miao; K Christopher Garcia; Sabine Tejpar; Mauro Delorenzi; Alan P Venook; Andrew B Nixon; Robert S Warren; Jeroen P Roose; Philippe Depeille
Journal:  JCI Insight       Date:  2019-06-25

2.  Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.

Authors:  Yongzhi Han; Jing Fang; Zhiwei Xiao; Jian Deng; Minghui Zhang; Lixiong Gu
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.553

3.  Hierarchical closeness-based properties reveal cancer survivability and biomarker genes in molecular signaling networks.

Authors:  Tien-Dzung Tran; Yung-Keun Kwon
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

Review 4.  Application and prospects of single cell sequencing in tumors.

Authors:  Ruo Han Huang; Le Xin Wang; Jing He; Wen Gao
Journal:  Biomark Res       Date:  2021-12-11

5.  Molecular Targets and Mechanisms of Hedyotis diffusa-Scutellaria barbata Herb Pair for the Treatment of Colorectal Cancer Based on Network Pharmacology and Molecular Docking.

Authors:  Zhenpeng Yang; Shuai Lu; Huazhen Tang; Jinxiu Qu; Bing Wang; Yuying Wang; Guofeng Pan; Benqiang Rao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-06       Impact factor: 2.650

6.  Oncogenic KRAS suppresses store-operated Ca2+ entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines.

Authors:  Cristina Pierro; Xuexin Zhang; Cynthia Kankeu; Mohamed Trebak; Martin D Bootman; H Llewelyn Roderick
Journal:  Cell Calcium       Date:  2018-03-14       Impact factor: 6.817

7.  Novel functional variants at the GWAS-implicated loci might confer risk to major depressive disorder, bipolar affective disorder and schizophrenia.

Authors:  Leonid O Bryzgalov; Elena E Korbolina; Ilja I Brusentsov; Elena Y Leberfarb; Natalia P Bondar; Tatiana I Merkulova
Journal:  BMC Neurosci       Date:  2018-04-19       Impact factor: 3.288

8.  JNK, p38, ERK, and SGK1 Inhibitors in Cancer.

Authors:  Jonas Cicenas; Egle Zalyte; Arnas Rimkus; Dalius Dapkus; Remigijus Noreika; Sigitas Urbonavicius
Journal:  Cancers (Basel)       Date:  2017-12-21       Impact factor: 6.639

9.  Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing.

Authors:  Shunqiao Feng; Lin Han; Mei Yue; Dixiao Zhong; Jing Cao; Yibing Guo; Yanling Sun; Hao Zhang; Zhenhua Cao; Xiaodai Cui; Rong Liu
Journal:  Orphanet J Rare Dis       Date:  2021-06-11       Impact factor: 4.123

10.  The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.

Authors:  Guangyu Wang; Dandan Xu; Zicheng Zhang; Xinhui Li; Jiaqi Shi; Jie Sun; Huan-Zhong Liu; Xiaobo Li; Meng Zhou; Tongsen Zheng
Journal:  NPJ Precis Oncol       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.